Two medications in the same family, built on different mechanisms, with a real head-to-head trial behind the comparison. Neither one is the answer for everybody, and the honest version of this comparison includes the parts that make each a poor fit.
Both are FDA-approved medications in the GLP-1 class used for weight management. Tirzepatide adds a second hormone pathway (GIP) and produced greater average weight loss in clinical trials. Semaglutide has the longer track record. The right one depends on your health profile, how you tolerate it, and what you can access.
Your gut releases hormones after you eat. They tell your brain you are full, tell your stomach to empty more slowly, and tell your pancreas how much insulin to release. Both of these medications are lab-made versions of those signals, held at a steady level so the message keeps arriving.
Semaglutide mimics one of those hormones, GLP-1. The practical effect for most patients is reduced appetite, slower stomach emptying, and a quieter version of the food noise that makes eating decisions exhausting.
Tirzepatide acts on two pathways: GLP-1 and GIP. GIP is a second gut hormone involved in how the body handles insulin and stores fat. Acting on both is the structural difference between the two drugs, and it is the reason the outcomes differ.
Worth knowing: both are peptides. If you have read our peptide therapy page, this is the same category of medicine, just the part of it with the largest evidence base.
These two were compared directly. SURMOUNT-5 was a 72-week head-to-head trial in adults with obesity or overweight who did not have type 2 diabetes. Participants taking tirzepatide lost more weight on average than those taking semaglutide, roughly twenty percent of body weight against roughly fourteen percent, and tirzepatide also came out ahead on the secondary measures the trial tracked, including waist circumference.
Read those numbers as group averages from a controlled trial, not as a forecast for you. Trial participants receive structured support, consistent dose escalation, and close monitoring. Individual results vary widely, some people respond strongly to semaglutide and modestly to tirzepatide, and a medication you cannot tolerate does nothing for you regardless of what a trial average says.
Semaglutide's advantage is time. It has been in wide clinical use longer, across both diabetes and weight management indications, which means a deeper body of real-world safety and outcomes data. For some patients and some medical histories, that longer record carries weight.
The profiles are broadly similar, and the common effects for both are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort. They usually show up early, follow dose increases, and settle as the body adapts. Slow, deliberate titration is the single most useful tool for managing them, which is one reason a program that escalates you quickly to hit a number is doing you no favors.
Both medications also carry the same class warnings on their FDA labels, including a boxed warning about thyroid C-cell tumors observed in rodent studies and contraindications tied to that finding. We cover the warnings, who should avoid these medications entirely, and what proper monitoring looks like in our companion guide, is semaglutide safe.
Access is a real part of this decision. Insurance coverage for weight management differs from plan to plan, and the medication yours will cover is sometimes the deciding factor between two reasonable options.
Compounded versions of these medications are widely advertised, and here the distinctions matter. A compounded preparation is not the FDA-approved product, and federal rules on what may be compounded tightened after the GLP-1 shortages were declared resolved. Legitimate compounding happens through licensed pharmacies, for a documented patient-specific need, under current federal rules. That is a different world from research-chemical websites and offshore sellers shipping vials with no exam, no labs, and nobody to call when something goes wrong.
Our position is the same one our medical director applies to every prescription in this practice: we work within current FDA rules and source through professional compounding pharmacies, and when the rules change, we change with them. If that means telling you an option is off the table right now, we will tell you.
The choice is not made from a dropdown menu. In our medical weight loss program, it comes out of three things:
Then we talk it through: what each option asks of you, what the evidence says, what the side effects tend to feel like in the first month, and what happens if it is not working at week twelve. You choose, we guide it safely. Results vary from person to person, and we do not promise a number.
In SURMOUNT-5, the 72-week head-to-head trial in adults with obesity or overweight without type 2 diabetes, tirzepatide produced greater average weight loss than semaglutide. Those are group averages from a controlled trial rather than a forecast for you. The medication that suits you depends on your history, your tolerance, and what you can access and stay on.
Switching is common, and it is a clinical decision rather than a self-service one. Your provider looks at why the current medication is not working, whether the dose was fully titrated, how your side effects have been, and your history. Doses do not transfer directly between the two, so a switch comes with its own titration plan and follow-up.
Broadly similar, and mostly gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal discomfort. They tend to appear early, track with dose increases, and ease as your body adjusts. Both also carry the same class warnings on their FDA labels, including the boxed warning about thyroid C-cell tumors seen in rodent studies. Details are in our safety guide.
No. A compounded preparation is not the FDA-approved product, and federal rules on what may be compounded have tightened since the shortages were resolved. Legitimate compounding runs through licensed pharmacies for a documented patient-specific need. Unregulated online sellers are a different thing entirely, and we do not use them.
Labs, a full history, and an in-person exam, in that order. We review thyroid and pancreatic history, gallbladder history, kidney function, current medications, pregnancy plans, and prior experience with these drugs, then we talk through the options together. If neither medication is appropriate for you, we will say so and tell you what we would do instead.
Beach Glo is physician-owned, with Dr. Kalnoky, MD on site and a family medicine practice next door for ten years. His Florida license is public record, and we link to it.
Physician-supervised programs with labs, an in-person exam, and monitored titration.
Learn more →What the FDA label warns about, who should not take it, and what supervision should look like.
Read the guide →The wider category these medications belong to, held to the same medical standard.
Learn more →Online booking takes about a minute, and your appointment is confirmed on the spot.